Missouri Map Round 3, Surrogacy Stay Denied, Insulin Antitrust & Legal AI Deals: Week of Sep 23

Better Call Claude Briefing — Week of Sep 23, 2026

Missouri’s midterms map fight is back at the Supreme Court for a third time this month, a California surrogacy custody fight stays with the intended parents after an emergency denial, Florida sues over insulin list-price economics, and European and U.S. legal-tech vendors keep pouring capital and agents into lawyer workflows. General news roundup only — not legal advice.

Missouri map returns to SCOTUS for round three

Challengers to Missouri’s Trump-backed 2025 congressional map asked the U.S. Supreme Court late Tuesday to block an Eighth Circuit ruling that would force the state to use that map in the November midterms. The justices have already paused the new districts twice this month, including a Sept. 10 order that left in place a Missouri Supreme Court decision requiring the older 2022 lines unless voters approve the redraw in a referendum. The Eighth Circuit nonetheless held that using a different map in November than in the August primary would violate Article I’s “chosen by the People” clause, and ordered a permanent injunction while staying enforcement for about a week. Absentee voting is already underway under the 2022 lines, and more than a million potential voters could be reshuffled if the new map returns. The Court gave map supporters until midday Wednesday to respond.

Sources: CBS/AP, Reuters, SCOTUSblog, Eighth Circuit opinion PDF

Justice Kagan denies stay in California–Texas surrogacy custody fight

Justice Elena Kagan on Tuesday refused an emergency request from surrogate McKenna West to freeze a California court order naming intended parents Omar Ahmed and Nausheen Gilkar as the legal parents of a five-week-old boy born in Dallas. West had refused the couple’s request to terminate the pregnancy after a severe fetal heart diagnosis and later sought conservatorship and a role in medical decisions for the child, who was born with hypoplastic left heart syndrome. California trial and appellate courts had already declined to stay parentage for the couple; Kagan’s one-line denial, typical of the emergency docket, left that order in force while the underlying appeals continue. The dispute sits at the intersection of surrogacy contracts, abortion bans that shaped where the birth occurred, and who controls life-saving care for a critically ill newborn.

Sources: ABC7 / AP, TimesLIVE

Florida AG sues insulin makers, PBMs, and rebate firms over list-price scheme

Florida Attorney General James Uthmeier filed suit in Miami-Dade Circuit Court against Eli Lilly, Novo Nordisk, and Sanofi, plus pharmacy benefit managers CVS Caremark, Express Scripts, and OptumRx, and rebate aggregators Zinc, Ascent, and Emisar. The complaint alleges the companies inflated published list prices for insulin and related diabetes and GLP-1 drugs while circulating large rebates for preferred formulary placement — so uninsured patients and people with deductibles or coinsurance paid the sticker price while manufacturers and middlemen shared the spread. The AG’s office cites roughly 2.3 million Florida adults with diabetes and points to testimony that roughly three-quarters of a sample Humalog list price went out as rebates and discounts. Claims include the Florida Deceptive and Unfair Trade Practices Act and the Florida Antitrust Act; the state seeks an injunction, restitution, disgorgement, damages, and civil penalties.

Sources: WFLA, Bloomberg Law

Noxtua closes €100M+ Series C as C.H.BECK takes majority stake

Berlin legal-AI company Noxtua said it closed a Series C of more than €100 million, with German publisher C.H.BECK becoming majority shareholder and Austrian publisher MANZ joining as a new investor. The company — spun out of Oxford and Imperial College research, with more than 30,000 users across six European offices — builds jurisdiction-specific Legal AI Workspaces on curated publisher databases rather than raw LLM recall alone, and emphasizes citations, BSI C5 / ISO security certifications, and European data-residency options for firms and courts. Leadership framed the round as funding pan-European expansion and deeper publisher product ties while existing VC and law-firm investors exit. The deal is a clear signal that European legal publishers see exclusive content plus AI as the way to compete with U.S. legal-AI platforms and general-purpose model labs.

Sources: Tech.eu

Casepoint ships first purpose-built eDiscovery AI agents

Casepoint announced that its Casepoint IQ platform now includes live Relevance Determination and Issue Coding agents for government and legal review teams, with early-access customers already using them inside the company’s eDiscovery application. The Relevance agent scores documents for responsiveness with reasoning and likelihood scores; the Issue Coding agent maps documents to matter-specific factual or legal issues and can run post-run recall/precision QC per code. Both use a multi-model cross-check pipeline, require sample-set validation before full runs, and keep an audit trail of human and AI decisions inside the customer’s existing security boundary. Casepoint pitches the release as the first pieces of a broader agent portfolio meant to chain relevance analysis into issue coding and later review steps without hopping tools — a practical step in the industry’s move from chatbots to governed, auditable agents.

Sources: PR Newswire / Casepoint

---

This Briefing is general news for Better Call Claude readers. It is not legal advice, and nothing here creates an attorney-client relationship. Check primary sources and talk to a licensed lawyer about your situation.